Camille Sureau Selected Research

Antiviral Agents (Antivirals)

3/2021	Identification of Anti-Severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Oxysterol Derivatives In Vitro.
1/2020	Combined small molecule and loss-of-function screen uncovers estrogen receptor alpha and CAD as host factors for HDV infection and antiviral targets.
1/2018	Nucleic Acid Polymers Are Active against Hepatitis Delta Virus Infection In Vitro.
1/2018	Nucleic acid polymer REP 2139 and nucleos(T)ide analogues act synergistically against chronic hepadnaviral infection in vivo in Pekin ducks.
1/2017	A new class of hepatitis B and D virus entry inhibitors, proanthocyanidin and its analogs, that directly act on the viral large surface proteins.
1/2017	Inhibition of hepatitis B viral entry by nucleic acid polymers in HepaRG cells and primary human hepatocytes.
12/2016	HDV RNA replication is associated with HBV repression and interferon-stimulated genes induction in super-infected hepatocytes.
10/2016	Solute Carrier NTCP Regulates Innate Antiviral Immune Responses Targeting Hepatitis C Virus Infection of Hepatocytes.
12/2015	A Novel Tricyclic Polyketide, Vanitaracin A, Specifically Inhibits the Entry of Hepatitis B and D Viruses by Targeting Sodium Taurocholate Cotransporting Polypeptide.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Camille Sureau Research Topics

Disease

32	Infections 10/2023 - 12/2006
8	Hepatitis B 04/2023 - 01/2009
6	Hepatocellular Carcinoma (Hepatoma) 12/2021 - 01/2012
3	Virus Diseases (Viral Diseases) 01/2022 - 01/2019
3	Neoplasms (Cancer) 03/2021 - 01/2016
3	Viremia 10/2020 - 01/2017
2	Fibrosis (Cirrhosis) 03/2021 - 01/2018
2	Coinfection 01/2020 - 01/2019
2	Liver Diseases (Liver Disease) 01/2018 - 01/2016
2	Reinfection 12/2015 - 02/2013
1	COVID-19 03/2021
1	Insulin Resistance 01/2020
1	Hypoxia (Hypoxemia) 01/2020
1	Hepatitis D 10/2018
1	Hepatitis 01/2018
1	Chronic Hepatitis B 04/2016

Drug/Important Bio-Agent (IBA)

9	Antiviral Agents (Antivirals)IBA 03/2021 - 12/2015
6	Proteins (Proteins, Gene)FDA Link 01/2022 - 12/2006
5	sodium-bile acid cotransporterIBA 01/2021 - 12/2015
4	AntibodiesIBA 04/2023 - 01/2008
4	RNA (Ribonucleic Acid)IBA 01/2019 - 01/2008
4	InterferonsIBA 01/2018 - 10/2016
3	Nucleic AcidsIBA 01/2018 - 01/2017
3	Membrane Proteins (Integral Membrane Proteins)IBA 01/2018 - 01/2009
3	PolymersIBA 01/2018 - 01/2017
2	OxysterolsIBA 10/2023 - 03/2021
2	VaccinesIBA 04/2023 - 02/2013
2	Hepatitis delta Antigens (HDAg)IBA 01/2019 - 10/2018
2	Amino Acids FDA Link 01/2019 - 12/2009
2	Peptides (Polypeptides)IBA 01/2019 - 01/2018
2	N-(4-aminophenethyl)spiroperidol (NAPS)IBA 01/2018 - 01/2017
2	entecavir FDA Link 01/2018 - 01/2017
2	Hepatitis B Surface Antigens (HBsAg)FDA Link 01/2017 - 01/2016
2	Hepatitis B e AntigensIBA 12/2016 - 01/2016
1	Synthetic Vaccines (Recombinant Vaccines)IBA 04/2023
1	GeneVac BIBA 04/2023
1	Engerix-BIBA 04/2023
1	Immunoglobulins (Immunoglobulin)IBA 04/2023
1	Alitretinoin FDA Link 01/2022
1	Bexarotene (LGD1069)FDA Link 01/2022
1	LuciferasesIBA 01/2022
1	Small Interfering RNA (siRNA)IBA 01/2022
1	KinesinsIBA 01/2022
1	exophillic acidIBA 01/2022
1	CholesterolIBA 03/2021
1	Broadly Neutralizing AntibodiesIBA 10/2020
1	Viral AntigensIBA 01/2020
1	Estrogen Receptor alphaIBA 01/2020
1	GlycosaminoglycansIBA 01/2020
1	RNA Polymerase II (RNA Polymerase B)IBA 01/2020
1	Mitogen-Activated Protein KinasesIBA 01/2020
1	EpitopesIBA 01/2020
1	pyrimidineIBA 01/2020
1	Phosphatidylinositols (Phosphatidylinositol)IBA 01/2020
1	Epidermal Growth Factor (EGF)IBA 01/2019
1	myrcludex-BIBA 01/2019
1	Protein SIBA 10/2018
1	LigandsIBA 01/2018
1	REP 2139IBA 01/2018
1	2,4-thiazolidinedione (thiazolidinedione)IBA 01/2018
1	Tenofovir (Viread)FDA Link 01/2018
1	Troglitazone (Rezulin)FDA Link 01/2018
1	Surface Antigens (Surface Antigen)IBA 01/2018
1	CoumarinsIBA 01/2018
1	EnzymesIBA 01/2018
1	ImmunosorbentsIBA 01/2018
1	Sirolimus (Rapamycin)FDA Link 01/2018
1	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2018
1	OligonucleotidesIBA 01/2017
1	proanthocyanidinIBA 01/2017
1	Interferon-alpha (Interferon Alfa)IBA 01/2017
1	Hepatitis B virus P proteinIBA 01/2017
1	DNA (Deoxyribonucleic Acid)IBA 12/2016
1	Bile Acids and Salts (Bile Acids)IBA 10/2016
1	Therapeutic UsesIBA 04/2016
1	Monoclonal AntibodiesIBA 04/2016
1	GlypicansIBA 01/2016
1	Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric 01/2016
1	Dimethyl Sulfoxide (DMSO)FDA LinkGeneric 01/2016
1	vanitaracin AIBA 12/2015
1	PolyketidesIBA 12/2015
1	PF-429242IBA 03/2015
1	Ritonavir (Norvir)FDA Link 06/2014
1	Irbesartan FDA LinkGeneric 06/2014
1	Ezetimibe (Zetia)FDA Link 06/2014
1	Proteoglycans (Proteoglycan)IBA 03/2013
1	Alanine (L-Alanine)FDA Link 03/2013
1	Heparin (Liquaemin)FDA LinkGeneric 03/2013
1	Heparitin Sulfate (Heparan Sulfate)IBA 03/2013
1	Blood Group Antigens (Blood Groups)IBA 01/2012
1	TetraspaninsIBA 01/2008
1	DisulfidesIBA 12/2007
1	Sulfhydryl Compounds (Thiols)IBA 12/2007

Therapy/Procedure

7	Therapeutics 12/2021 - 01/2009
1	Aftercare (After-Treatment) 01/2018